Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 104

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 104
---
 reducing the predictive accuracy of these underlying factors and indicators. Consequently, our estimates of the annual total addressable market and our forecasts of market growth and future revenue from our products and services, including our research services may prove to be incorrect, and our key business metrics may not reflect our actual performance. For example, if the annual total addressable market or the potential market growth for our products and services is smaller than we have estimated or if the key business metrics we utilize to forecast revenue are inaccurate, it may impair our sales growth and have an adverse impact on our business, financial condition, results of operations and growth prospects. 28 We have a history of losses, and we may not be able to achieve or sustain profitability. The Company has historically incurred significant losses: $4,516,095 and $1,291,932 for the fiscal years ended June 30, 2024 and 2023, respectively. The Company has also recorded accumulated deficits of $6,941,483 and $3,588,427 as of June 30, 2024 and 2023, respectively. Additionally, the Company’s recurring cash outflows from operations amounted to $1,885,895 and $1,306,705 for the years ended June 30, 2024 and 2023. Historically, we have devoted most of our financial resources to the research and development of our clinical genetics products and services, as well as to develop Rewell, our preventative health business. The discovery and development of safe and effective healthcare is a complex and uncertain process, which takes many years and involves significant costs. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we continue to expand research and development efforts, enhance our existing consumer products, services and business model, broaden our customer base, work with regulatory agencies, and hire additional employees to support our growth. Any future losses may have an adverse effect on our shareholders’ equity and working capital, which could negatively impact our operations and your investment in us. A failure to sustain or grow our revenue levels and to maintain profitability may negatively affect our business, financial condition, results of operations and cash flows, and could cause the market price of our common share to decline. Our prospects must be considered in light of the risks and difficulties frequently encountered by companies in a similar stage of development, particularly companies in new and rapidly evolving markets such as ours. These risks include an evolving and unpredictable business model and the management of growth. To address these risks we must (i) increase